Newest studies

Prediction of Alzheimer's disease progression within 6 years using speech: A novel approach leveraging language models

57/100 ✓ Peer-reviewed Digital health tools Alzheimer's & dementia : the journal of the Alzheimer's Association

Key finding: The proposed method offers a fully automated procedure, providing an opportunity to develop an inexpensive, broadly accessible, and easy-to-administer screening tool for MCI-to-AD progression prediction, facilitating development of remote assessment.

• Digital Tools
• Early Stage

Full summary, score breakdown and related studies → Original source

Anti-acetylated-tau immunotherapy is neuroprotective in tauopathy and brain injury

43/100 ✓ Peer-reviewed Drug development Molecular neurodegeneration

Key finding: Anti-ac-tauK174 treatment mitigates neurobehavioral impairment and reduces tau pathology in PS19 mice. +3 more findings

• Treatments
• Brain Biology

Full summary, score breakdown and related studies → Original source

Cerebrospinal fluid p-tau181, 217, and 231 in definite Creutzfeldt-Jakob disease with and without concomitant pathologies

54/100 ✓ Peer-reviewed Biomarkers Alzheimer's & dementia : the journal of the Alzheimer's Association

Key finding: N-terminal p-tau was increased in CJD versus SCD (p < 0.0001) and correlated with total tau (t-tau) in the presence of AD and PART co-pathology (rho = 0.758-0.952, p ≤ 001). +4 more findings

• Biomarkers
• Brain Biology

Full summary, score breakdown and related studies → Original source

A systematic review of the role of TREM2 in Alzheimer's disease

50/100 ✓ Peer-reviewed TREM2 and immune genetics Chinese medical journal

Key finding: This review substantiates the evolving understanding of TREM2's disease progression-dependent impacts.

• Genetics
• Brain Biology

Full summary, score breakdown and related studies → Original source

Retina Fundus Photograph-Based Artificial Intelligence Algorithms in Medicine: A Systematic Review

65/100 ✓ Peer-reviewed Digital health tools Ophthalmology and therapy

Key finding: We found that the use of AI algorithms for the interpretation of retinal images, compared to clinical data and physician experts, represents an innovative solution with demonstrated superior accuracy in identifying many ophthalmic (e.g., diabetic retinopathy (DR), age-related macular degeneration (AMD), optic nerve disorders), and non-ophthalmic disorders (e.g., dementia, cardiovascular disease). +1 more finding

• Digital Tools

Full summary, score breakdown and related studies → Original source

Retraction Note: A specific amyloid-beta protein assembly in the brain impairs memory

16/100 ⚠ Retracted — do not rely on it Laboratory science Nature

Key finding: Original paper published in Nature, March 16, 2006 (vol. 440, pages 352-357) +4 more findings

• Brain Biology

Scored 17 on our rubric, shown as 16: non-peer-reviewed sources are capped at 16. See the breakdown.

Full summary, score breakdown and related studies → Original source

Exploring the gut-brain Axis: Potential therapeutic impact of Psychobiotics on mental health

43/100 ✓ Peer-reviewed Disease mechanisms Progress in neuro-psychopharmacology & biological psychiatry

Key finding: One of the most challenging and controversial issues in microbiome research is related to gut microbial metabolism and neuropsychological disorders. +4 more findings

• Treatments

Full summary, score breakdown and related studies → Original source

Visual dysfunction in dementia with Lewy bodies

43/100 ✓ Peer-reviewed Brain scans and imaging Current neurology and neuroscience reports

Key finding: These symptoms are associated with visual hallucinations, driving impairment, falls, and other negative outcomes. +1 more finding

• Other Dementias
• Early Stage

Full summary, score breakdown and related studies → Original source

Longitudinal Genome-Wide Association Study of Cognitive Impairment after Subarachnoid Hemorrhage

73/100 ✓ Peer-reviewed Genetics Biomedicines

Key finding: Cognitive impairment was observed in 65 patients (42.5%) during a mean follow-up of 37.7 ± 12.4 months. +4 more findings

• Genetics

Full summary, score breakdown and related studies → Original source

Effects of time of the day at sampling on CSF and plasma levels of Alzheimer' disease biomarkers

52/100 ✓ Peer-reviewed Biomarkers Alzheimer's research & therapy

Key finding: Importantly, Aβ42/Aβ40 ratio remained unaltered, suggesting that it is more suitable for implementation in clinical workup than individual Aβ peptides. +3 more findings

• Biomarkers

Full summary, score breakdown and related studies → Original source

Repurposing Metformin for the Treatment of Atrial Fibrillation: Current Insights

43/100 ✓ Peer-reviewed Drug development Vascular health and risk management

Key finding: Prospective clinical data from the United Kingdom Prospective Diabetes Study (UKPDS), completed in 1998, demonstrated that metformin not only has excellent therapeutic efficacy as an anti-diabetes drug but also that good glycemic control reduced the risk of micro- and macro-vascular complications, especially in obese patients and thereby reduced the risk of diabetes-associated cardiovascular disease (CVD).

• Treatments
• Risk Factors

Full summary, score breakdown and related studies → Original source

Tau-targeting nanoparticles for treatment of Alzheimer's disease

43/100 ✓ Peer-reviewed Drug development Exploration (Beijing, China)

Key finding: There is no cure; current treatments manage symptoms and slow cognitive decline. +4 more findings

• Treatments
• Brain Scans
• Brain Biology

Full summary, score breakdown and related studies → Original source

Multifaceted roles of APOE in Alzheimer disease

51/100 ✓ Peer-reviewed Genetics Nature reviews. Neurology

Key finding: The APOEε4 allele significantly increases AD risk, whereas the ε2 allele is protective relative to the most common ε3 allele.

• Genetics
• Brain Biology

Full summary, score breakdown and related studies → Original source

KLOTHO KL-VS heterozygosity is associated with diminished age-related neuroinflammation, neurodegeneration, and synaptic dysfunction in older cognitively unimpaired adults

53/100 ✓ Peer-reviewed Biomarkers Alzheimer's & dementia : the journal of the Alzheimer's Association

Key finding: Higher levels of neuroinflammation, neurodegeneration, and synaptic dysfunction in older adults were attenuated in KL-VS HET . +3 more findings

• Brain Biology
• Biomarkers
• Early Stage

Full summary, score breakdown and related studies → Original source

Comparative effectiveness of glucagon-like peptide-1 agonists, dipeptidyl peptidase-4 inhibitors, and sulfonylureas on the risk of dementia in older individuals with type 2 diabetes in Sweden: an emulated trial study

62/100 ✓ Peer-reviewed Drug development EClinicalMedicine

Key finding: The pooled trial included 88,381 participants who received prescriptions for GLP-1 agonists (n = 12,351), DPP-4 inhibitors (n = 43,850), or sulfonylureas (n = 32,216) at baseline and were followed for an average of 4.3 years. +4 more findings

• Risk Factors
• Clinical Trials

Full summary, score breakdown and related studies → Original source

Sulfopropanoic acid derivatives for treating neurodegenerative disorders: a patent spotlight

43/100 ✓ Peer-reviewed Clinical trials Pharmaceutical patent analyst

Key finding: Clinical trials showed that ALZ-801 oral tablet is well tolerated and showed superior pharmacokinetic properties in healthy volunteers and Alzheimer's disease (AD) patients. +1 more finding

• Clinical Trials
• Treatments

Full summary, score breakdown and related studies → Original source

Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer's Disease

66/100 ✓ Peer-reviewed Treatments Drugs

Key finding: The enrolled population of 84 subjects (31 homozygotes and 53 heterozygotes) was 52% females, mean age 69 years, MMSE 25.7 [70% mild cognitive impairment (MCI), 30% mild AD] with 55% on cholinesterase inhibitors. +4 more findings

• Clinical Trials
• Biomarkers
• Treatments

Full summary, score breakdown and related studies → Original source

APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer's Disease

72/100 ✓ Peer-reviewed Genetics New England Journal of Medicine

Key finding: Clinical data supported a delayed onset of cognitive impairment in persons who were heterozygous for the APOE3 Ch variant in a kindred with a high prevalence of autosomal dominant Alzheimer's disease. +2 more findings

• Genetics

Full summary, score breakdown and related studies → Original source

Annexin A11 aggregation in FTLD-TDP type C and related neurodegenerative disease proteinopathies

46/100 ✓ Peer-reviewed Brain tissue and pathology Acta neuropathologica

Key finding: Finally, we found abundant annexin A11 inclusions as the primary pathologic finding in a case of progressive supranuclear palsy-like frontotemporal dementia with prominent striatal vacuolization due to a novel variant, ANXA11 p.P75S. +2 more findings

• Other Dementias
• Brain Biology

Full summary, score breakdown and related studies → Original source

Impact of cognitive impairment on driving behaviour and route choices of older drivers: a real-world driving study

48/100 ✓ Peer-reviewed Risk factors Scientific Reports

Key finding: Maintaining driving independence is important for older adults. +1 more finding

Full summary, score breakdown and related studies → Original source

Genetic influences on brain and cognitive health and their interactions with cardiovascular conditions and depression

63/100 ✓ Peer-reviewed Genetics Nature communications

Key finding: Here we combine multiple data resources, including genotyping and postmortem gene expression, to map the genetic landscape of brain structure and identify 367 loci associated with cortical thickness and 13 loci associated with white matter hyperintensities (P < 5×10-8), with several loci also showing a significant association with cognitive function. +2 more findings

• Genetics
• Risk Factors

Full summary, score breakdown and related studies → Original source

Plasma extracellular vesicle tau and TDP-43 as diagnostic biomarkers in FTD and ALS

62/100 ✓ Peer-reviewed Disease mechanisms Nature medicine

Key finding: Taken together, the combination of EV TDP-43 levels and EV 3R/4R tau ratios may aid the molecular diagnosis of FTD, FTD spectrum disorders and ALS, providing a potential biomarker to monitor disease progression and target engagement in clinical trials.

• Brain Biology
• Diagnosis
• Biomarkers

Full summary, score breakdown and related studies → Original source

Advances in blood biomarkers for Alzheimer disease (AD): A review

46/100 ✓ Peer-reviewed Biomarkers The Kaohsiung journal of medical sciences

Key finding: Consequently, blood biomarkers have emerged as promising tools for non-invasive and cost-effective diagnosis, prognosis, and monitoring of AD progression. +4 more findings

• Biomarkers
• Brain Biology

Full summary, score breakdown and related studies → Original source

Perceptions of cognitive decline among American Indian and Alaska Native elders

54/100 ✓ Peer-reviewed Disparities Alzheimer's & dementia (Amsterdam, Netherlands)

Key finding: Participants indicated that they are concerned about cognitive decline, are willing to plan for their future care and cognitive testing, and articulated a desire for Tribally led long-term support services. +3 more findings

Full summary, score breakdown and related studies → Original source

Relationships between PET and blood plasma biomarkers in corticobasal syndrome

50/100 ✓ Peer-reviewed Biomarkers Alzheimer's & dementia : the journal of the Alzheimer's Association

Key finding: CBS Aβ+ group showed a reduced Aβ42/40 ratio, with elevated phosphorylated tau (p-tau)181, glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) concentrations, while CBS Aβ- group only showed elevated NfL concentration compared to CU. +4 more findings

• Biomarkers
• Brain Scans

Full summary, score breakdown and related studies → Original source